Investigation of the onset of pregnancy and changes during subsequent outcomes in the background of administration of cyclophosphamide and doxorubicin to female white rats

The article presents information about a scientific study conducted to study changes in the course of pregnancy and its outcomes after administration of cyclophosphamide and doxorubicin to female white rats for therapeutic purposes. Women taking antitumor drugs from the cytostatic group may become pregnant during treatment. Given the conflicting opinions about the effect of these drugs on pregnant women and the fetus, it was determined how the therapeutic use of cyclophosphamide and doxorubicin, which are representatives of the cytostatic group, individually and in combination, depending on the dose, affects the onset, course of pregnancy and fetal development in the prenatal and early postnatal periods. Since cytostatics, when used together, cause a sharp decrease in the amount of sex hormones, no pregnancies have been observed against the background of their use. The results of our studies show that compared with the use of a dose of 2.5 mg/ kg of doxorubicin and a dose of 10 mg/ kg of cyclophosphamide, cyclophosphamide has a stronger effective, teratogenic effect.